Skip to main content
SpringerLink
Log in

Therapeutic Management of Obesity

  • Chapter
  • First Online:
Therapeutic Lipidology

Part of the book series: Contemporary Cardiology ((CONCARD))

Abstract

Obesity is a chronic relapsing disease process that is increasing in prevalence, affecting both adults and children. It is the result of a small positive energy imbalance from too much food, or too little activity causes obesity that occurs over time. The food we eat provides the energy for obesity, but food is more than “energy.” Focusing on calories alone may not be as productive as focusing on the role of sugar and fat. Obesity increases risk of death and of many diseases, and weight loss provides benefits in reducing health risks and improving the quality of life. Effective treatment must redress the energy imbalance with diet, lifestyle modification, exercise, medications, and surgery. Five drugs are approved by the FDA for long-term treatment of obesity, and they can effectively improve health-related risks. Bariatric surgery has become a major treatment strategy and can reduce long-term health risks from obesity.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 249.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Bray GA, Heisel WE, Afshin A, Jensen MD, Dietz WH, Long M, Kushner RF, Daniels SR, Wadden TA, Tsai AG, Hu FB, Jakicic JM, Ryan DH, Wolfe BM, Inge TH. The science of obesity management: an endocrine society scientific statement. Endocr Rev. 2018;39(2):79–132.

    Article  PubMed  PubMed Central  Google Scholar 

  2. Ng M, Fleming T, Robinson M, et al. Global regional, and national prevalence of overweight and obesity in children and adults during 1980-2013: a systematic analysis of the global burden of disease study 2013. Lancet. 2014;384:766–81.

    Article  PubMed  PubMed Central  Google Scholar 

  3. Hales CM, Fryar CD, Carroll MD, Freedman DS, Ogden CL. Trends in obesity and severe obesity prevalence in US youth and adults by sex and age, 2007-2008 to 2015-2016. JAMA. 2018;319(16):1723–5.

    Article  PubMed  PubMed Central  Google Scholar 

  4. Martin CB, Herrick KA, Sarafrazi N, Ogden CL. Attempts to lose weight among adults in the United States, 2013-2016. NCHS Data Brief. 2018;313:1–8.

    Google Scholar 

  5. Ogden CL, Carroll MD, Kit BK, Flegal KM. Prevalence of childhood and adult obesity in the United States, 2011-2012. JAMA. 2014;311:806–14.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Schwartz MW, Seeley RJ, Zeltser LM, Drewnowski A, Ravussin E, Redman LM, Leibel RL. Obesity pathogenesis: an endocrine society scientific statement. Endocr Rev. 2017;38(4):267–96. https://doi.org/10.1210/er.2017-00111.

    Article  PubMed  PubMed Central  Google Scholar 

  7. Bray GA. The metabolic syndrome and obesity. Totowa: Humana Press; 2007.

    Book  Google Scholar 

  8. Bray FA. Medical consequences of obesity. J Clin Endocrinol. 2004;89:2583–9.

    Article  CAS  Google Scholar 

  9. Atkins RCD. Atkins' diet revolution: the high calorie way to stay thin forever. New York: David McKay Co; 1972.

    Google Scholar 

  10. Polivy J, Herman CP. The effects of resolving to diet on restrained and unrestrained eaters: the "false hope syndrome". Int J Eat Disord. 1999 Dec;26(4):434–47.

    Article  CAS  PubMed  Google Scholar 

  11. Bray GA. Obesity is a chronic, relapsing neurochemical disease. Intern J Obes. 2004;28:34–8.

    Article  CAS  Google Scholar 

  12. Bray GA, Kim KK, Wilding JPH. Obesity: a chronic relapsing progressive disease process: a position paper of world obesity. Obes Rev. 2017;18(7):715–23.

    Article  CAS  PubMed  Google Scholar 

  13. Bray GA, Fruhbeck G, Ryan DH, Wilding JPH. Management of obesity. Lancet. 2016. Publ on line 8 Feb 2016. PMID:26868660.

    Google Scholar 

  14. Sahakyan KR, Somers VK, Rodriguez-Escudero JP, et al. Normal-weight central obesity: implications for total and cardiovascular mortality. Ann Intern Med. 2015:e-pub 10 Nov 2015. https://doi.org/10.7326/M14-2525.

  15. Finkelstein EA, Graham WC, Malhotra R. Lifetime direct medical costs of childhood obesity. Pediatrics. 2014;133:854–62.

    Article  PubMed  Google Scholar 

  16. Bray GA and Bouchard C. The Biology of Human Overfeeding. In prep.

    Google Scholar 

  17. Church TS, Thomas DM, Tudor-Locke C, et al. Trends over 5 decades in U.S. occupation-related physical activity and their associations with obesity. PLoS One. 2011;6:e19657. Epub 2011 May 25.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Bray GA. From farm to fat cell: why aren't we all fat? Metabolism. 2015;64:349–53.

    Article  CAS  PubMed  Google Scholar 

  19. Keith SW, Redden DT, Katzmarzyk PT, et al. Putative contributors to the secular increase in obesity: exploring the roads less traveled. Int J Obes. 2006;30:1585–94.

    Article  CAS  Google Scholar 

  20. Rogers PJ, Hogenkamp PS, de Graaf C, et al. Does low-energy sweetener consumption affect energy intake and body weight? A systematic review, including meta-analyses, of the evidence from human and animal studies. Intern J Obes. 2016;40:381–94.

    Article  CAS  Google Scholar 

  21. Ailhaud G, Guesnet P. Fatty acid composition of fats is an early determinant of childhood obesity: a short review and an opinion. Obes Rev. 2004;5(1):21–6. Review.

    Article  CAS  PubMed  Google Scholar 

  22. Bray GA, Popkin BM. Dietary fat affects obesity rate. Am J Clin Nutr. 1999;70(4):572–3.

    Article  CAS  PubMed  Google Scholar 

  23. Rosqvist F, Iggman D, Kullberg J, Cedernaes J, Johansson HE, Larsson A, Johansson L, Ahlström H, Arner P, Dahlman I, Risérus U. Overfeeding polyunsaturated and saturated fat causes distinct effects on liver and visceral fat accumulation in humans. Diabetes. 2014;63(7):2356–68. https://doi.org/10.2337/db13-1622. Epub 2014 Feb 18.

    Article  PubMed  Google Scholar 

  24. Goldstone AP, Beales PL. Genetic obesity syndromes. Front Horm Res. 2008;36:37–60.

    Article  CAS  PubMed  Google Scholar 

  25. Loos RJ. The genetics of adiposity. Curr Opin Genet Dev. 2018;50:86–95.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Klein S, Burke LE, Bray GA, et al. American heart association council on nutrition, physical activity, and metabolism. Clinical implications of obesity with specific focus on cardiovascular disease: a statement for professionals from the American heart association council on nutrition, physical activity, and metabolism: endorsed by the American college of cardiology foundation. Circulation. 2004;110:2952–67.

    Article  PubMed  Google Scholar 

  27. Jensen MD, Ryan DH, Donato KA, et al. Guidelines (2013) for managing overweight and obesity in adults. Obesity. 2014;22(S2):S1–S410.

    Article  Google Scholar 

  28. Foster GD, Wadden TA, Phelan S, Sarwer DB, Sanderson RS. Obese patients' perceptions of treatment outcomes and the factors that influence them. Arch Intern Med. 2001;161(17):2133–9.

    Article  CAS  PubMed  Google Scholar 

  29. Johnston BC, Kanters S, Bandayrel K, et al. Comparison of weight loss among named diet programs in overweight and obese adults: a meta-analysis. JAMA. 2014;312:923–33.

    Article  PubMed  CAS  Google Scholar 

  30. Bray GA, Siri-Tarino PW. The role of macronutrient content in the diet for weight management. Endocrinol Metab Clin N Am. 2016;45:581–604. https://doi.org/10.1016/j.ecl.2016.04.009. Review

    Article  Google Scholar 

  31. US News and World Report 2019: Jan 2.

    Google Scholar 

  32. Estruch R, Ros E, Salas-Salvadó J, Covas MI, Corella D, Arós F, Gómez-Gracia E, Ruiz-Gutiérrez V, Fiol M, Lapetra J, Lamuela-Raventos RM, Serra-Majem L, Pintó X, Basora J, Muñoz MA, Sorlí JV, Martínez JA, Fitó M, Gea A, Hernán MA, Martínez-González MA, PREDIMED Study Investigators. Primary prevention of cardiovascular disease with a mediterranean diet supplemented with extra-virgin olive oil or nuts. N Engl J Med. 2018;378(25):e34. https://doi.org/10.1056/NEJMoa1800389. Epub 2018 Jun 13. PMID:29897866.

    Article  CAS  PubMed  Google Scholar 

  33. Appel LJ, Moore TJ, Obarzanek E, Vollmer W, Svetkey LP, Sacks F, Bray G, Vogt TM, Cutler JA, Simons-Morton D, Lin PH, Karanja N, Miller ER III, Harsha DW. A clinical trial of the effects of dietary patterns on blood pressure. New Engl J Med. 1997;338:1117–24.

    Article  Google Scholar 

  34. Forrestall CA. Flexitarian diet and weight control: healthy or risky eating behavior. Frontiers Nutr. 2018;5:59.

    Article  Google Scholar 

  35. Ello-Martin RLS, Ledikwe JH, Beach AM, Rolls BJ. Dietary energy density in the treatment of obesity: a year-long trial comparing 2 weight-loss diets. Am J Clin Nutr. 2007;85:1465–77.

    Article  CAS  PubMed  Google Scholar 

  36. Dansinger ML, Gleason JA, Griffith JL, Selker HP, Schaefer EJ. Comparison of the Atkins, Ornish, Weight Watchers, and Zone diets for weight loss and heart disease risk reduction: a randomized trial. JAMA. 2005;293:43–53.

    Article  CAS  PubMed  Google Scholar 

  37. Sacks FM, Bray GA, Carey VJ, et al. Comparison of weight-loss diets with different compositions of fat, protein, and carbohydrates. N Engl J Med. 2009;360:859–73.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  38. Gardner CD, Trepanowski JF, Del Gobbo LC, Hauser ME, Rigdon J, Ioannidis JPA, Desai M, King AC. Effect of low-fat vs low-carbohydrate diet on 12-month weight loss in overweight adults and the association with genotype pattern or insulin secretion: the DIETFITS randomized clinical trial. JAMA. 2018;319(7):667–79. https://doi.org/10.1001/jama.2018.0245. Erratum in: JAMA. 2018 Apr 3;319(13):1386. JAMA. 2018;319(16):1728 PMID:29466592.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  39. Hall KD, Guo J. Obesity energetics: body weight regulation and the effects of diet composition. Gastroenterology. 2017;152(7):1718–27.

    Article  PubMed  Google Scholar 

  40. Ebbeling CB, Feldman HA, Klein GL, Wong JMW, Bielak L, Steltz SK, Luoto PK, Wolfe RR, Wong WW, Ludwig DS. Effects of a low carbohydrate diet on energy expenditure during weight loss maintenance: randomized trial. BMJ. 2018;363:k4583. https://doi.org/10.1136/bmj.k4583.

    Article  PubMed  PubMed Central  Google Scholar 

  41. Hall KD, Guo J. No significant effect of dietary carbohydrate versus fat on the reduction in total energy expenditure during maintenance of lost weight. 2018; https://doi.org/10.1101/476655.

  42. The Look AHEAD Research Group, Wadden TA, Bantle JP, Blackburn GL, et al. Eight-year weight losses with an intensive lifestyle intervention: the look AHEAD study. Obesity. 2014;22:5–13.

    Article  Google Scholar 

  43. Diabetes Prevention Program Research Group, Knowler WC, Fowler SE, Hamman RF, et al. 10-year follow-up of diabetes incidence and weight loss in the diabetes prevention program outcomes study. Lancet. 2009;374:1677–86.

    Article  PubMed Central  Google Scholar 

  44. Tate DF, Jackvony EH, Wing RR. Effects of internet behavioral counseling on weight loss in adults at risk for type 2 diabetes: a randomized trial. JAMA. 2003;289:1833–6.

    Article  PubMed  Google Scholar 

  45. Jakicic JM, Marcus BH, Gallagher KI, Napolitano M, Lang W. Effect of exercise duration and intensity on weight loss in overweight, sedentary women: a randomized trial. JAMA. 2003;290:1323–30.

    Article  CAS  PubMed  Google Scholar 

  46. Apovian CM, Aronne LJ, Bessesen DH, et al. Pharmacologic management of obesity: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2015; https://doi.org/10.1210/jc.2014-3415.

  47. Dong Z, Xu L, Liu H, Lv Y, Zheng Q, Li L. Comparative efficacy of five long-term weight loss drugs: quantitative information for medication guidelines. Obes Rev. 2017;18(12):1377–85. https://doi.org/10.1111/obr.12606. Epub 2017 Oct 10.

    Article  CAS  PubMed  Google Scholar 

  48. Sjostrom L, Rissanen A, Andersen T, Boldrin M, Golay A, Koppeschaar HP, Krempf M. Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. European Multicentre Orlistat Study Group Lancet. 1998;352:167–72.

    CAS  Google Scholar 

  49. Torgerson JS, Hauptman J, Boldrin MN, Sjostrom L. XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care. 2003;27:155–61.

    Article  Google Scholar 

  50. Padwal R, Kezouh A, Levine M, Etminan M. Long-term persistence with orlistat and sibutramine in a population-based cohort. Int J Obes. 2007;31:1567–70.

    Article  CAS  Google Scholar 

  51. Smith SR, Weissman NJ, Anderson CM, Sanchez M, Chuang E, Stubbe S, Bays H, Shanahan WR. Multicenter, placebo-controlled trial of lorcaserin for weight management. N Engl J Med. 2010;363:245–56.

    Article  CAS  PubMed  Google Scholar 

  52. Fidler MC, Sanchez M, Raether B, Weissman NJ, Smith SR, Shanahan WR, Anderson CM. A one-year randomized trial of lorcaserin for weight loss in obese and overweight adults: the BLOSSOM trial. J Clin Endocrinol Metabol. 2011;96:3067–77.

    Article  CAS  Google Scholar 

  53. O'Neil PM, Smith SR, Weissman NJ, Fidler MC, Sanchez M, Zhang J, Raether B, Anderson CM, Shanahan WR. Randomized placebo-controlled clinical trial of lorcaserin for weight loss in type 2 diabetes mellitus: the BLOOM-DM study. Obesity. 2012;20:1426–36.

    Article  CAS  PubMed  Google Scholar 

  54. FDA . FDA Briefing information: meeting of the Endocrinologic and Metabolic Drugs advisory Committee.2012.; http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/EndocrinologicandMetabolicDrugsAdvisoryCommittee/UCM303198.pdf

  55. Astrup A, Carraro R, Finer N, Harper A, Kunesova M, Lean ME, Niskanen L, Rasmussen MF, Rissanen A, Rossner S, Savolainen MJ, Van Gaal L. Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide. Int J Obes. 2012;36:843–54.

    Article  CAS  Google Scholar 

  56. Pi-Sunyer X, Astrup A, Fujioka K, Greenway F, Halpern A, Krempf M, Lau DCW, le Roux CW, Violante Ortiz R, Jensen CB, Wilding JPH. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. N Engl J Med. 2015;373:11–22.

    Article  PubMed  CAS  Google Scholar 

  57. Wadden TA, Hollander P, Klein S, Niswender K, Woo V, Hale PM, Aronne L. Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: the SCALE maintenance randomized study. Int J Obes. 2013;37:1443–51.

    Article  CAS  Google Scholar 

  58. Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JF, Nauck MA, Nissen SE, Pocock S, Poulter NR, Ravn LS, Steinberg WM, Stockner M, Zinman B, Bergenstal RM, Buse JB. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375:311–22.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  59. Marso SP, Bain SC, Consoli A, Eliaschewitz FG, Jodar E, Leiter LA, Lingvay I, Rosenstock J, Seufert J, Warren ML, Woo V, Hansen O, Holst AG, Pettersson J, Vilsboll T. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016;375:1834–44.

    Article  CAS  PubMed  Google Scholar 

  60. Gadde KM, Allison DB, Ryan DH, Peterson CA, Troupin B, Schwiers ML, Day WW. Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial. Lancet. 2011;377:1341–52.

    Article  CAS  PubMed  Google Scholar 

  61. Allison DB, Gadde KM, Garvey WT, Peterson CA, Schwiers ML, Najarian T, Tam PY, Troupin B, Day WW. Controlled-release phentermine/topiramate in severely obese adults: a randomized controlled trial (EQUIP). Obesity. 2011;20:330–42.

    Article  PubMed  CAS  Google Scholar 

  62. Garvey WT, Ryan DH, Look M, Gadde KM, Allison DB, Peterson CA, Schwiers M, Day WW, Bowden CH. Two-year sustained weight loss and metabolic benefits with controlled-release phentermine/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study. Am J Clin Nutr. 2011;95:297–308.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  63. Greenway FL, Fujioka K, Plodkowski RA, Mudaliar S, Guttadauria M, Erickson J, Kim DD, Dunayevich E. Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2010;376:595–605.

    Article  CAS  PubMed  Google Scholar 

  64. Wadden TA, Foreyt JP, Foster GD, Hill JO, Klein S, O'Neil PM, Perri MG, Pi-Sunyer FX, Rock CL, Erickson JS, Maier HN, Kim DD, Dunayevich E. Weight loss with naltrexone SR/bupropion SR combination therapy as an adjunct to behavior modification: the COR-BMOD trial. Obesity. 2010;19:110–20.

    Article  PubMed  CAS  Google Scholar 

  65. Apovian CM, Aronne L, Rubino D, Still C, Wyatt H, Burns C, Kim D, Dunayevich E. A randomized, phase 3 trial of naltrexone SR/bupropion SR on weight and obesity-related risk factors (COR-II). Obesity (Silver Spring). 2013;21:935–43.

    Article  CAS  Google Scholar 

  66. Hollander P, Gupta AK, Plodkowski R, Greenway F, Bays H, Burns C, Klassen P, Fujioka K. Effects of naltrexone sustained-release/bupropion sustained-release combination therapy on body weight and glycemic parameters in overweight and obese patients with type 2 diabetes. Diabetes Care. 2013;36:4022–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  67. Nissen SE, Wolski KE, Prcela L, Wadden T, Buse JB, Bakris G, Perez A, Smith SR. Effect of naltrexone-bupropion on major adverse cardiovascular events in overweight and obese patients with cardiovascular risk factors. JAMA. 2016;315:990.

    Article  CAS  PubMed  Google Scholar 

  68. Khera R, Murad MH, Chandar AK, Dulai PS, Wang Z, Prokop LJ, Loomba R, Camilleri M, Singh S. Association of pharmacological treatments for obesity with weight loss and adverse events. JAMA. 2016;315:2424.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  69. Garvey WT, Mechanick JI, Brett EM, Garber AJ, Hurley DL, Jastreboff AM, Nadolsky K, Pessah-Pollack R, Plodkowski R. American Association of Clinical Endocrinologists and American College of Endocrinology comprehensive clinical practice guidelines for medical care of patients with obesity executive summary. Complete guidelines available at https://www.aace.com/publications/guidelines. Endocr Pract. 2016;22:842–84.

    Article  PubMed  Google Scholar 

  70. Nguyen NT, Masoomi H, Magno CP, Nguyen XM, Laugenour K, Lane J. Trends in use of bariatric surgery, 2003-2008. J Am Coll Surg. 2011;213:261–6.

    Article  PubMed  Google Scholar 

  71. Chang SH, Stoll CR, Song J, Varela JE, Eagon CJ, Colditz GA. The effectiveness and risks of bariatric surgery: an updated systematic review and meta-analysis, 2003–2012. JAMA Surg. 2014;149:275–87.

    Article  PubMed  PubMed Central  Google Scholar 

  72. National Institutes Of Health. Gastrointestinal surgery for severe obesity consensus statement. Nutr Today. 1991;26:32-35.

    Google Scholar 

  73. Rubino F, Nathan DM, Eckel RH, Schauer PR, Alberti KG, Zimmet PZ, Del Prato S, Ji L, Sadikot SM, Herman WH, Amiel SA, Kaplan LM, Taroncher-Oldenburg G, Cummings DE. Delegates of the 2nd diabetes surgery summit. Metabolic surgery in the treatment algorithm for type 2 diabetes: a joint statement by international diabetes organizations. Obes Surg. 2017 Jan;27(1):2–21.

    Article  PubMed  Google Scholar 

  74. Styne DM, Arslanian SA, Connor EL, Farooqi IS, Murad MH, Silverstein JH, Yanovski JA. Pediatric obesity-assessment, treatment, and prevention: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2017;102:709–57.

    Article  PubMed  PubMed Central  Google Scholar 

  75. Smith MD, Patterson E, Wahed AS, Belle SH, Bessler M, Courcoulas AP, Flum D, Halpin V, Mitchell JE, Pomp A, Pories WJ, Wolfe B. Relationship between surgeon volume and adverse outcomes after rygb in longitudinal assessment of bariatric surgery (labs) study. Surg Obes Relat Dis. 2010;6:118–25.

    Article  PubMed  Google Scholar 

  76. Gletsu-Miller N, Wright BN. Mineral malnutrition following bariatric surgery. Advances in Nutrition: An International Review Journal. 2013;4:506–17.

    Article  CAS  Google Scholar 

  77. Mechanick JI, Youdim A, Jones DB, Garvey WT, Hurley DL, McMahon MM, Heinberg LJ, Kushner R, Adams TD, Shikora S, Dixon JB, Brethauer S. Clinical practice guidelines for the perioperative nutritional, metabolic, and nonsurgical support of the bariatric surgery patient-2013 update: cosponsored by American Association of Clinical Endocrinologists, the Obesity Society, and American Society for Metabolic and Bariatric Surgery. Obesity. 2013;21:S1–S27.

    Article  CAS  PubMed  Google Scholar 

  78. Courcoulas AP, Christian NJ, O’Rourke RW, Dakin G, Patchen Dellinger E, Flum DR, Melissa Kalarchian PD, Mitchell JE, Patterson E, Pomp A, Pories WJ, Spaniolas K, Steffen K, Wolfe BM, Belle SH. Preoperative factors and 3-year weight change in the longitudinal assessment of bariatric surgery (LABS) consortium. Surg Obes Relat Dis. 2015;11:1109–18.

    Article  PubMed  PubMed Central  Google Scholar 

  79. Mitchell JE, Christian NJ, Flum DR, Pomp A, Pories WJ, Wolfe BM, Courcoulas AP, Belle SH. Postoperative behavioral variables and weight change 3 years after bariatric surgery. Journal of the American Medical Association Surgery. 2016;151:752.

    PubMed  Google Scholar 

  80. Sjöström L. Review of the key results from the Swedish Obese Subjects (SOS) trial - a prospective controlled intervention study of bariatric surgery. J Intern Med. 2013;273:219–34.

    Article  PubMed  Google Scholar 

  81. Schauer PR, Bhatt DL, Kirwan JP, Wolski K, Aminian A, Brethauer SA, Navaneethan SD, Singh RP, Pothier CE, Nissen SE, Kashyap SR. Bariatric surgery versus intensive medical therapy for diabetes - 5-year outcomes. N Engl J Med. 2017;376:641–51.

    Article  PubMed  PubMed Central  Google Scholar 

  82. Pories WJ, Swanson MS, MacDonald KG, Long SB, Morris PG, Brown BM, Barakat HA, deRamon RA, Israel G, Dolezal JM, Dohm L. Who would have thought it? An operation proves to be the most effective therapy for adult-onset diabetes mellitus. Ann Surg. 1995;222:339–52.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  83. Shoar S, Saber AA. Long-term and midterm outcomes of laparoscopic sleeve gastrectomy versus Roux-en-Y gastric bypass: a systematic review and meta-analysis of comparative studies. Surg Obes Relat Dis. 2017 Feb;13(2):170–80.

    Article  PubMed  Google Scholar 

  84. Sjöström L, Narbro K, Sjöström CD, Karason K, Larsson B, Wedel H, Lystig T, Sullivan M, Bouchard C, Carlsson B, Bengtsson C, Dahlgren S, Gummesson A, Jacobson P, Karlsson J, Lindroos A-K, Lönroth H, Näslund I, Olbers T, Stenlöf K, Torgerson J, Ågren G, Carlsson LMS. Effects of bariatric surgery on mortality in Swedish obese subjects. N Engl J Med. 2007;357:741–52.

    Article  PubMed  Google Scholar 

  85. Sjöström L, Gummesson A, Sjöström CD, Narbro K, Peltonen M, Wedel H, Bengtsson C, Bouchard C, Carlsson B, Dahlgren S, Jacobson P, Karason K, Karlsson J, Larsson B, Lindroos AK, Lönroth H, Näslund I, Olbers T, Stenlöf K, Torgerson J, Carlsson LM, Study SOS. Effects of bariatric surgery on cancer incidence in obese patients in Sweden (Swedish Obese Subjects Study): a prospective, controlled intervention trial. Lancet Oncol. 2009 Jul;10(7):653–62.

    Article  PubMed  Google Scholar 

  86. Shikora SA, Wolfe BM, Apovian CM, Anvari M, Sarwer DB, Gibbons RD, Ikramuddin S, Miller CJ, Knudson MB, Tweden KS, Sarr MG, Billington CJ. Sustained weight loss with vagal nerve blockade but not with sham: 18-month results of the recharge trial. J Obes. 2015;2015:365604.

    Article  PubMed  PubMed Central  Google Scholar 

  87. Saber AA, Shoar S, Almadani MW, Zundel N, Alkuwari MJ, Bashah MM, Rosenthal RJ. Efficacy of first-time intragastric balloon in weight loss: a systematic review and meta-analysis of randomized controlled trials. Obes Surg. 2016;27:277–87.

    Article  Google Scholar 

  88. Mion F, Ibrahim M, Marjoux S, Ponchon T, Dugardeyn S, Roman S, Deviere J. Swallowable Obalon® gastric balloons as an aid for weight loss: a pilot feasibility study. Obes Surg. 2013;23:730–3.

    Article  PubMed  Google Scholar 

  89. Rajagopalan H, Cherrington AD, Thompson CC, Kaplan LM, Rubino F, Mingrone G, Becerra P, Rodriguez P, Vignolo P, Caplan J, Rodriguez L, Galvao Neto MP. Endoscopic duodenal mucosal resurfacing for the treatment of type 2 diabetes: 6-month interim analysis from the first-in-human proof-of-concept study. Diabetes Care. 2016;39:2254–61.

    Article  CAS  PubMed  Google Scholar 

  90. Klein S, Fontana L, Young VL, Coggan AR, Kilo C, Patterson BW, Mohammed BS. Absence of an effect of liposuction on insulin action and risk factors for coronary heart disease. N Engl J Med. 2004;350:2549–57.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Clinical Obesity, Pennington Center Louisiana State University, Baton Rouge, LA, USA

    George A. Bray

Authors
  1. George A. Bray
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to George A. Bray .

Editor information

Editors and Affiliations

  1. The University of Chicago Pritzker School of Medicine, Chicago, IL, USA

    Michael H. Davidson

  2. Cicarrone Center for the Prevention of Cardiovascular Disease, Johns Hopkins Univerity School of Medicine, Baltimore, MD, USA

    Peter P. Toth

  3. Department of Applied Health Science, Indiana University School of Public Health, Bloomington, IN, USA

    Kevin C. Maki

Rights and permissions

Reprints and permissions

Copyright information

© 2021 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Bray, G.A. (2021). Therapeutic Management of Obesity. In: Davidson, M.H., Toth, P.P., Maki, K.C. (eds) Therapeutic Lipidology. Contemporary Cardiology. Humana, Cham. https://doi.org/10.1007/978-3-030-56514-5_17

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-56514-5_17

  • Published:

  • Publisher Name: Humana, Cham

  • Print ISBN: 978-3-030-56513-8

  • Online ISBN: 978-3-030-56514-5

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation